(NASDAQ: VERA) Vera Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.62%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Vera Therapeutics's revenue in 2026 is $0.On average, 14 Wall Street analysts forecast VERA's revenue for 2026 to be $3,362,992,586, with the lowest VERA revenue forecast at $713,770,737, and the highest VERA revenue forecast at $9,192,037,023. On average, 14 Wall Street analysts forecast VERA's revenue for 2027 to be $19,252,472,513, with the lowest VERA revenue forecast at $9,090,711,976, and the highest VERA revenue forecast at $38,157,442,928.
In 2028, VERA is forecast to generate $49,945,399,117 in revenue, with the lowest revenue forecast at $26,611,382,451 and the highest revenue forecast at $82,415,795,385.